<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668926</url>
  </required_header>
  <id_info>
    <org_study_id>EKNZ 2015-00015</org_study_id>
    <nct_id>NCT02668926</nct_id>
  </id_info>
  <brief_title>Endocrine and Emotional Effects of Lisdexamfetamine and d-Amphetamine.</brief_title>
  <acronym>LisDex</acronym>
  <official_title>Endocrine and Emotional Effects of Lisdexamfetamine and d- Amphetamine: a Placebo-controlled Study in Healthy Subjects (LisDexStudy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the acute emotional and endocrine effects of equivalent doses of
      lisdexamfetamine and amphetamine in healthy subjects. In addition the pharmacokinetics and
      effects of the amphetamines on aspects of social cognition are investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of lisdexamphetamine and d-Amphetamine on circulating steroidal hormones</measure>
    <time_frame>13 hours</time_frame>
    <description>Measurement of different circulating hormones before and after drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective effects of lisdexamphetamine and d-amphetamine</measure>
    <time_frame>13 hours</time_frame>
    <description>Assessment of subjective effects using visual analog scales</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of lisdexamphetamine and d-Amphetamine on emotion recognition and empathy</measure>
    <time_frame>1h</time_frame>
    <description>Assessment of emotion recognition and empathy using different Computer Tasks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>13h</time_frame>
    <description>Collection of blood samples for measurement of plasma concentrations</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lisdexamfetamine, d-amphetamine, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>d-amphetamine, Placebo, Lisdexamfetamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Lisdexamfetamine, d-amphetamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisdexamfetamine, d-amphetamine, Placebo</intervention_name>
    <description>Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.</description>
    <arm_group_label>Lisdexamfetamine, d-amphetamine, Placebo</arm_group_label>
    <other_name>Lisdexamfetamine=Elvanse, d-amphetamine=d-amphetamine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d-amphetamine, Placebo, Lisdexamfetamine</intervention_name>
    <description>Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.</description>
    <arm_group_label>d-amphetamine, Placebo, Lisdexamfetamine</arm_group_label>
    <other_name>Lisdexamfetamine=Elvanse, d-amphetamine=d-amphetamine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, Lisdexamfetamine, d-amphetamine</intervention_name>
    <description>Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.</description>
    <arm_group_label>Placebo, Lisdexamfetamine, d-amphetamine</arm_group_label>
    <other_name>Lisdexamfetamine=Elvanse, d-amphetamine=d-amphetamine sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        healthy subjects aged 18-45 years

        Exclusion Criteria:

          1. Chronic or acute medical condition including clinically relevant abnormality in
             physical exam, laboratory values, or ECG.

          2. Current or previous psychotic or major affective disorder

          3. Psychotic or major affective disorder in first-degree relatives

          4. Prior illicit drug use (cannabis) more than 5 times or any time within the previous 2
             months.

          5. Pregnant or nursing women.

          6. Participation in another clinical trial (currently or within the last 30 days)

          7. Use of medications that are contraindicated or otherwise interfere with the effects of
             the study medications (monoamine oxidase inhibitors, antidepressants, sedatives etc.)

          8. Tobacco smoking (&gt;10 cigarettes/day)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias E Liechti, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alex Odermatt, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

